Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances (Follow-up announcement)
Non-consolidated Financial Results for the Three Months Ended November 30, 2025
Chordia Therapeutics, Sep-Nov (1Q) Ordinary Profit Loss Narrows
By FISCO Corporation Notice of Distribution of Our Corporate Research Report
(Delayed)Notice of Investigator Meeting for rogocekib Development
Notice Regarding the Recording of Non-Operating Income (Grant income)
Corporate Governance Report
(Delayed)Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2025
Announcement on the Reduction of Capital Reserve and Appropriation of Surplus
Publication of Research on the Discovery of CLK Inhibitor Rogocekib (Follow-up announcement)
Fiscal year ended August 2025 Financial Results Presentation
Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2025 [Japanese GAAP]
Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances
Chordia Therapeutics, The Current Fiscal Year's Net Income to Widen
Notice regarding the Publication of the Revised Clinical Trial Protocol Summary for rogocekib
Publication of Research on the Discovery of CLK Inhibitor Rogocekib
Notice of Commencement of Joint Research with Senju Pharmaceutical Co., Ltd.
Chordia Therapeutics, Sep-May (Cumulative 3Q) Net Income Loss Widens, Mar-May Net Income Loss Widens
Non-consolidated Financial Results for the Nine Months Ended May 31, 2025 [Japanese GAAP]
Notice of Commencement of Joint Research with D. Western Therapeutics Institute, Inc.